Hoffmann-La Roche posts results of Phase 3 alectinib rollover study
Results for the study were first posted on ClinicalTrials.gov on October 9, 2026. The completed Phase 3 rollover study enrolled 50 participants and compared alectinib with crizotinib in patients with ALK- or RET-positive cancer.
Primary source
ClinicalTrials.gov results record, October 9, 2026
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Read the source: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation